Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAPRI: 18F-Florbetaben PET for Cardiac Amyloidosis
NCT03616496Completed
- Sponsor
- CHRU de Nancy - Hôpital Central
- Start
- Jun 2019
- Primary completion
- Jan 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label trial of flutemetamol in cardiac amyloidosis (3 arms), sponsored by CHRU de Nancy - Hôpital Central. Primary endpoint: Definitive diagnosis of cardiac ATTR- or AL-amyloidosis at 24 months. Started Jun 2019; status: completed.
02
Drugs
flutemetamol
03
Conditions
cardiac amyloidosis
Beyond the preview
Go deeper on NCT03616496.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03616496.